Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
9.19
USD
|
-2.13%
|
|
-18.96%
|
+22.08%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
744.1
|
1,057
|
172.7
|
57.79
|
76.05
|
190.7
|
-
|
-
|
Enterprise Value (EV)
1 |
578
|
626.9
|
-132.4
|
-127.8
|
-20.47
|
42
|
55.22
|
190.7
|
P/E ratio
|
-11.4
x
|
-7.86
x
|
-1.19
x
|
-0.37
x
|
-0.65
x
|
-1.7
x
|
-1.61
x
|
-1.54
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,976
x
|
-
|
23
x
|
-
|
21.1
x
|
-
|
19.1
x
|
12.7
x
|
EV / Revenue
|
2,312
x
|
-
|
-17.7
x
|
-
|
-5.69
x
|
-
|
5.52
x
|
12.7
x
|
EV / EBITDA
|
-8.63
x
|
-5.51
x
|
0.94
x
|
0.85
x
|
0.17
x
|
-0.38
x
|
-0.37
x
|
-1.2
x
|
EV / FCF
|
-8.45
x
|
-6.88
x
|
1.08
x
|
1.07
x
|
0.22
x
|
-0.54
x
|
-1.06
x
|
-0.94
x
|
FCF Yield
|
-11.8%
|
-14.5%
|
92.8%
|
93.8%
|
448%
|
-184%
|
-94.2%
|
-107%
|
Price to Book
|
4.22
x
|
2.12
x
|
0.55
x
|
0.32
x
|
0.91
x
|
1.46
x
|
1.8
x
|
-
|
Nbr of stocks (in thousands)
|
6,459
|
9,748
|
9,815
|
9,973
|
10,103
|
20,755
|
-
|
-
|
Reference price
2 |
115.2
|
108.4
|
17.60
|
5.795
|
7.528
|
9.190
|
9.190
|
9.190
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/29/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.25
|
-
|
7.5
|
-
|
3.6
|
-
|
10
|
15
|
EBITDA
1 |
-66.97
|
-113.8
|
-141.5
|
-150.6
|
-118.3
|
-111
|
-151
|
-159
|
EBIT
1 |
-68.54
|
-118
|
-146.1
|
-157.1
|
-124
|
-116.9
|
-147.5
|
-177
|
Operating Margin
|
-27,418%
|
-
|
-1,948.29%
|
-
|
-3,444.19%
|
-
|
-1,474.7%
|
-1,179.94%
|
Earnings before Tax (EBT)
1 |
-64.49
|
-116.4
|
-145.5
|
-154.5
|
-118.2
|
-112.2
|
-141.4
|
-178.1
|
Net income
1 |
-64.49
|
-117.5
|
-145.5
|
-154.5
|
-117.2
|
-111.2
|
-142.7
|
-172.8
|
Net margin
|
-25,794.4%
|
-
|
-1,940.53%
|
-
|
-3,254.58%
|
-
|
-1,427.23%
|
-1,152.21%
|
EPS
2 |
-10.10
|
-13.80
|
-14.80
|
-15.60
|
-11.60
|
-5.402
|
-5.717
|
-5.978
|
Free Cash Flow
1 |
-68.42
|
-91.14
|
-123
|
-119.9
|
-91.71
|
-77.26
|
-52.01
|
-203.6
|
FCF margin
|
-27,366.8%
|
-
|
-1,639.39%
|
-
|
-2,547.5%
|
-
|
-520.1%
|
-1,357.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/29/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
3.6
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-37.56
|
-33.1
|
-36.71
|
-42.42
|
-39.25
|
-32.23
|
-28.65
|
-31.53
|
-33.02
|
-25.15
|
-27
|
-27
|
-28
|
-29
|
-34
|
EBIT
1 |
-38.52
|
-34.42
|
-38.13
|
-44.02
|
-41.04
|
-33.94
|
-30.24
|
-33.06
|
-34.53
|
-26.16
|
-26.95
|
-28.2
|
-29.88
|
-31.84
|
-33.88
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-839.97%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-38.36
|
-34.41
|
-37.89
|
-43.74
|
-40.11
|
-32.72
|
-29.04
|
-31.49
|
-32.87
|
-24.85
|
-25.83
|
-26.77
|
-28.76
|
-30.81
|
-31.5
|
Net income
1 |
-38.36
|
-34.41
|
-37.91
|
-43.76
|
-40.13
|
-32.74
|
-29.06
|
-31.51
|
-32.88
|
-23.71
|
-25.81
|
-26.77
|
-28.51
|
-30.04
|
-32.62
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-807.11%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-3.900
|
-3.500
|
-3.800
|
-4.400
|
-4.000
|
-3.300
|
-2.900
|
-3.100
|
-3.300
|
-2.300
|
-1.422
|
-1.316
|
-1.334
|
-1.370
|
-1.550
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/4/21
|
3/29/22
|
5/12/22
|
8/11/22
|
11/10/22
|
3/30/23
|
5/11/23
|
8/10/23
|
11/9/23
|
3/18/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
166
|
430
|
305
|
186
|
96.5
|
149
|
136
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-68.4
|
-91.1
|
-123
|
-120
|
-91.7
|
-77.3
|
-52
|
-204
|
ROE (net income / shareholders' equity)
|
-
|
-38.6%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
27.30
|
51.00
|
32.30
|
18.10
|
8.280
|
6.300
|
5.100
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
19.2
|
11.8
|
15.1
|
11.8
|
0.81
|
0.8
|
0.7
|
0.6
|
Capex / Sales
|
7,698.8%
|
-
|
201.64%
|
-
|
22.44%
|
-
|
7%
|
4%
|
Announcement Date
|
3/12/20
|
3/1/21
|
3/29/22
|
3/30/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
9.19
USD Average target price
40
USD Spread / Average Target +335.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +22.08% | 191M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|